National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1) (No. PB 16 of 2012)

Overview

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No.1) was enacted to address the gap created by the introduction of price disclosure and price reductions for certain pharmaceutical brands under section 99ADH of the National Health Act 1953. This legislation, made pursuant to subsection 84AG(1) of the Act, aims to streamline the therapeutic groups by removing drugs that no longer require specific categorisation due to the application of new pricing regulations. This amendment ensures that therapeutic groups remain relevant and contain at least one listed drug as mandated by subsection 84AG(5) of the Act. The objective of this instrument, as outlined in the explanatory statement, is to maintain the integrity and relevance of the therapeutic groups within the Pharmaceutical Benefits Scheme by excluding drugs affected by the new pricing provisions. The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No.1) was enacted by the Commonwealth Parliament and is a legislative instrument under the Legislative Instruments Act 2003. This determination, also referred to as PB 16 of 2012, commenced on 1 April 2012 and includes amendments to the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010. The policy objective is to ensure that the therapeutic groups remain aligned with the current legislative framework, particularly in response to changes introduced by section 99ADH of the Act. The amendment process involved the removal of specific drugs and entire therapeutic groups that became redundant due to the new pricing regulations, thereby maintaining the efficacy and coherence of the therapeutic group definitions.

Scope and Application

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No.1) amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010, which determines therapeutic groups and the drugs listed within those groups. This determination applies to the pharmaceutical industry and healthcare providers within Australia, specifically targeting the classification and management of certain drugs under the National Health Act 1953. The amendments made by this determination are effective from 1 April 2012 and include the removal of specific drugs from their designated therapeutic groups and the elimination of certain groups altogether if they no longer contain any listed drugs. This process is in line with the legislative requirements under the Act to ensure therapeutic groups remain relevant and populated by at least one listed drug. The Act extends its reach across the Commonwealth of Australia, applying nationally to ensure consistency in the classification and management of pharmaceutical benefits. The amendments are minor and consequential to the implementation of price disclosure price reductions as stipulated under section 99ADH of the Act, and thus, they do not require additional consultation beyond what is already provided for in the legislative framework.

Key Provisions

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1) amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010) (section 3). This amendment is effective from 1 April 2012 (section 2) and is intended to remove certain drugs from their respective therapeutic groups, as well as removing the CCB group and the Statins group from the Principal Instrument (section 3). The CCB group, which refers to the Dihydropyridine calcium-channel blocker group, and the Statins group, which refers to the HMG Co-A reductase inhibitor group, are no longer considered therapeutic groups as they do not contain any listed drugs (section 3, Items 2 and 5). The obligations imposed by this amending instrument primarily concern the classification and listing of drugs within therapeutic groups. Under section 3, specific drugs are removed from their respective groups, and entire groups are removed if they no longer contain any listed drugs. The Pharmaceutical Benefits Scheme (PBS) must ensure that the therapeutic groups are updated and accurately reflect the current listings of drugs (section 3, Items 1-8). This involves reviewing and revising the Principal Instrument to remove the specified drugs and groups, ensuring that the updated information is disseminated to relevant stakeholders, and maintaining an up-to-date record of the therapeutic groups and their associated drugs. The amendment does not explicitly outline specific offences, penalties, or consequences for non-compliance with its provisions. However, non-compliance with the National Health Act 1953 or the Pharmaceutical Benefits Scheme regulations could lead to penalties under those broader legislative frameworks. Typically, breaches of the National Health Act or the PBS regulations might result in fines, legal action, or other civil or administrative penalties, depending on the nature and severity of the breach. The precise penalties would be governed by the overarching legislation rather than this specific amending instrument. It is important for entities and individuals involved in the PBS to stay informed about the amendments and ensure that their practices comply with the updated therapeutic groups and drug listings. Failure to adhere to the amended classifications could potentially affect the eligibility of patients for pharmaceutical benefits, the reimbursement processes for healthcare providers, and the overall administration of the PBS. Consequently, maintaining accurate records and ensuring compliance with the updated determination is crucial for all parties involved in the scheme.